Dyslipidaemia: PCSK9 antibodies: a dividend of the genomics revolution
- PMID: 24019032
- DOI: 10.1038/nrcardio.2013.139
Dyslipidaemia: PCSK9 antibodies: a dividend of the genomics revolution
Comment in
-
Beyond anti-PCSK9 therapies: the potential role of resistin inhibitors.Nat Rev Cardiol. 2014 Jan;11(1):12. doi: 10.1038/nrcardio.2013.139-c1. Epub 2013 Nov 12. Nat Rev Cardiol. 2014. PMID: 24217159 No abstract available.
Comment on
-
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.Lancet. 2012 Dec 8;380(9858):2007-17. doi: 10.1016/S0140-6736(12)61770-X. Epub 2012 Nov 6. Lancet. 2012. PMID: 23141813 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous